Bayer investors have spent the past week digesting a pair of regulatory green lights and a guidance upgrade. The harder question now is whether those medical breakthroughs can be converted into the cash needed to whittle down the group’s debt pile.
Bill Anderson, the company’s chief executive, made the strategic priority plain in comments reported by Reuters on 3 November: a break-up is not on the table for now. Innovation and deleveraging inside the existing group are the order of the day. That leaves shareholders betting on internal improvement — and on management’s ability to turn scientific progress into measurable financial relief.
Sunharbo Clears the FDA as a First-in-Class Stroke Treatment
The most closely watched development is the US approval of Asundexian, marketed as Sunharbo, for cutting the risk of recurrent strokes when used alongside an antiplatelet agent. Bayer describes it as the world’s first approved factor XIa inhibitor for this purpose. The green light rests on the Phase III OCEANIC-STROKE trial, which showed a 26% reduction in ischaemic strokes with a comparable rate of major bleeding — a combination that gives the drug genuine medical weight.
A second approval followed on 4 November, when China cleared Sevabertinib as a first-line treatment for adults with advanced HER2-mutated non-small cell lung cancer. That decision is based on results from the ongoing Phase I/II SOHO-01 study. Together the two rulings broaden the revenue base of the pharmaceuticals division, though their contribution will ultimately be judged on the income statement rather than in the regulatory file.
The Numbers Behind the Optimism
Hard figures lend the bull case some substance. In the third quarter of 2026 Bayer posted group revenue of EUR 10.053 billion and EBITDA before special items of EUR 1.615 billion. Earnings before special items rose 6.9%, while sales climbed 4.1% in nominal terms and 1.9% after adjusting for currency and portfolio effects. Pharmaceuticals drove the growth, and the division now serves both as the engine of expansion and as the yardstick against which investors measure expectations.
Guidance issued roughly a week ago sharpened those targets. Bayer lifted its outlook for the free cash flow and trimmed its forecast for net financial debt, while raising its expectations for the Pharmaceuticals margin to between 25% and 27%. For the group’s EBITDA before special items, management pencilled in a 2026 range of EUR 9.8 billion to EUR 10.3 billion.
Should investors sell immediately? Or is it worth buying Bayer?
Two Brokers, Two Verdicts
Analysts read the same news very differently. Deutsche Bank Research, according to media reports, raised its price target to EUR 65 and reiterated its buy recommendation, citing a third quarter that beat expectations and higher estimates for the final three months of the year, both powered by Pharmaceuticals. Jefferies, by contrast, kept its hold rating and a EUR 48.50 target. Its analyst Michael Leuchten called the Asundexian approval broadly expected, while acknowledging that it materially lowers the risk attached to Bayer’s pharma pipeline.
That split neatly captures the tension in the investment case. A regulatory win can strengthen the underlying business without automatically justifying a richer valuation. What matters more is whether the improved margin and cash-flow guidance is actually delivered.
Cash Flow Becomes the Deciding Metric
Which is why the free cash flow figure now carries more weight than any single approval. New medicines may brighten the outlook for the pharma division, but debt reduction depends on how operating progress translates into hard cash. That is where the innovation strategy and the financial targets meet — and where the strategy will be judged.
The stock has already gained 53% since the start of the year, raising the bar for execution. Further confidence would be justified mainly if the improved business expectations are confirmed in the accounts. Should operating growth slow or free cash flow fall short of the raised guidance, the link between pharma strength and deleveraging would come under strain.
The next real test arrives on 24 February 2027, when Bayer publishes its full-year 2026 results. Confirmation of the upgraded targets could act as a positive catalyst; weaker figures would heighten the risk that the pipeline advances while the hoped-for financial relief arrives more slowly. For now, faith in the innovation story holds only as long as Bayer can show it is paying off where it counts.
Ad
Bayer Stock: Buy or Sell?! New Bayer Analysis from November 11 delivers the answer:
The latest Bayer figures speak for themselves: Urgent action needed for Bayer investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 11.
Bayer: Buy or sell? Read more here...
